વર્તમાન કિંમત
લક્ષ્ય કિંમત
વિશ્લેષક ભાવના
8 રેટિંગ્સ: ખરીદો
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company is headquartered in Boston, Massachusetts.
e.g. Promoter holding
Loading chart...
વિશ્લેષક સર્વસંમતિ EPS અને આવક અનુમાન.
| Metric (B) | FY 2026 | FY 2026 | FY 2026 | FY 2026 | FY 2027 | FY 2027 |
|---|---|---|---|---|---|---|
| $-1.28 | $-0.85 | $-0.93 | $-1.03 | $-1.17 | $-4.44 | |
| 0 | 0 | 0 | 0 | 0 | 0 | |
| — | — | +0.0% | -2.3% | +3.3% | -1.8% |
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | JAerovate T... | JBIO | $1.03B | — | 2.33 | — | — | -89.20% | — |
| 2. | SSpyGlass P... | SGP | $1.10B | — | 4.77 | — | — | -43.00% | — |
| 3. | AAvalyn Pha... | AVLN | $1.35B | — | 3.38 | — | — | -68.30% | — |
| 4. | GGenerate B... | GENB | $1.56B | — | 3.41 | — | -1,382.00% | -81.70% | -56.20% |
| 5. | AAlto Neuro... | ANRO | $1.18B | — | 4.00 | — | — | -46.70% | — |
મિલિયનમાં એકત્રિત આંકડા / સ્ટેન્ડઅલોન જુઓ.
| Quarter (M) | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Sep 26 |
|---|---|---|---|---|---|---|---|---|
Revenue | 1.75 | 1.92 | 0.96 | 0.1 | 0 | 0 | 0 | 0 |
COGS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Gross Profit % | - | - | - | - | - | - | - | - |
| 38.88 | 46.73 | 43.45 | 36.48 | 37.48 | 39.67 | 46.74 | 56.67 | |
EBIT | -37.12 | -44.81 | -42.49 | -36.38 | -37.48 | -39.67 | -46.74 | -53.36 |
OPM % | -2115.16% | -2336.18% | -4430.34% | -36749.49% | - | - | - | - |
Non-Operating Income | 1.24 | 6.51 | 1.28 | 0.86 | 2.92 | 1.47 | -6.06 | 0.35 |
PBT | -35.88 | -38.3 | -41.2 | -35.52 | -34.56 | -38.2 | -52.8 | -53.01 |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.05 |
Tax Rate % | - | - | - | - | - | - | - | -0.09% |
Net Income | -35.93 | -38.44 | -41.23 | -35.46 | -33.52 | -38.26 | -52.79 | -53.06 |
NPM % | -2047.41% | -2003.91% | -4299.79% | -35820.2% | - | - | - | - |
મિલિયનમાં એકત્રિત આંકડા / સ્ટેન્ડઅલોન જુઓ.
| Period (M) | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
Revenue | 0 | 1.04 | 4.47 | 2.98 |
COGS | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 |
Gross Profit % | - | - | - | - |
| 122.78 | 134.48 | 139.69 | 164.13 | |
EBIT | -122.78 | -133.44 | -135.22 | -161.16 |
OPM % | - | -12867.79% | -3023.77% | -5415.19% |
Non-Operating Income | -1.54 | 7.95 | 6.37 | 11.58 |
PBT | -124.32 | -125.49 | -128.85 | -149.57 |
Income Tax | 0 | 0 | 0 | 0 |
Tax Rate % | - | - | - | - |
Net Income | -124.67 | -125.94 | -129.32 | -148.65 |
NPM % | - | -12144.46% | -2891.79% | -4994.86% |
મિલિયનમાં એકત્રિત આંકડા / સ્ટેન્ડઅલોન જુઓ.
| Period (M) | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| 241.04 | 52.55 | 59.14 | 41.69 | |
| 0 | 163.55 | 70.22 | 174.87 | |
| 0 | 0 | 0 | 0 | |
| 7.67 | 5.54 | 6.16 | 9.3 | |
| 68.44 | 64.88 | 61.92 | 43.93 | |
Total Assets | 317.15 | 286.52 | 197.44 | 269.79 |
| 0 | 0 | 0 | 0 | |
| -144.62 | -262.71 | -382.53 | -488.28 | |
| 4.76 | 0 | 0 | 0 | |
| 8.05 | 7.73 | 7.07 | 8.25 | |
| 448.96 | 541.5 | 572.89 | 749.82 | |
Total Liabilities | 317.15 | 286.52 | 197.44 | 269.79 |
મિલિયનમાં એકત્રિત આંકડા / સ્ટેન્ડઅલોન જુઓ.
| Period (M) | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| -99.84 | -112.73 | -117.47 | -129.47 | |
| 0 | 0 | 0 | 0 | |
| 182.72 | 92.08 | 26.98 | 215.65 | |
Net CFNet Cash Flow | 82.88 | -20.65 | -90.49 | 86.18 |
FCFFree Cash Flow | -112.87 | -117.78 | -118.23 | -130.7 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| - | 61.8% | 40.1% | 34.1% | |
| -0.03 | - | - | - | |
| 10.91 | 8.72 | 4.77 | 7.20 | |
| - | 0.00 | 0.02 | 0.01 | |
Cash Conversion | 0.80 | 0.90 | 0.91 | 0.87 |
Payout Ratio | - | - | - | - |
| - | - | 331.2% | -33.5% | |
| - | - | - | - | |
| - | - | - | - | |
| 1.00 | 3.00 | 3.00 | 4.00 | |
| - | - | 0.13 | -3.26 | |
| - | - | - | - | |
| - | -121.4% | -28.9% | -49.9% |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
Odyssey Therapeutics Inc ની માલિકી કોની પાસે છે, SEC ફાઇલિંગ્સ મુજબ
આ કંપની માટે હજુ SEC માલિકી ફાઇલિંગ્સ નથી.
Odyssey Therapeutics Inc ના SEC ફાઇલિંગ્સ અને અર્નિંગ્સ કૉલ ટ્રાન્સક્રિપ્ટ્સ
આ કંપની માટે હજુ SEC ફાઇલિંગ્સ નથી.
What recent news says about Odyssey Therapeutics Inc, scored for sentiment.